Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed with stopping rules for patient accrual or study continuation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Aged ≥18 years

• Solid renal mass consistent with RCC on either ultrasound, MRI, or CT

• Longest tumor diameter measures 4.1-7cm

• Tumor stage T1bN0M0 without vascular invasion, adenopathy, or distant metastatic disease

• For females of reproductive potential: use of highly effective contraception for at least 1 month prior to enrollment and agreement to use such a method during study participation

• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

Locations
United States
Alabama
University of Alabama at Birmingham
RECRUITING
Birmingham
California
Stanford Cancer Institute
RECRUITING
Stanford
Minnesota
Mayo Clinic
RECRUITING
Rochester
Pennsylvania
Thomas Jefferson Health
RECRUITING
Philadelphia
Contact Information
Primary
Evan Hudson, MS
evanhudson@uabmc.edu
205-9346499
Time Frame
Start Date: 2024-01-03
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 25
Treatments
Experimental: RCC Participants
Receive Trans-arterial embolization (TAE)
Related Therapeutic Areas
Sponsors
Leads: University of Alabama at Birmingham
Collaborators: Varian, a Siemens Healthineers Company

This content was sourced from clinicaltrials.gov